Repositorio Institucional de la Universidad de Oviedo

Five-year overall survival and overall survival by tumor response measures from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Autor(es) y otros:

Rimassa, Lorenza; Chan, Stephen; Sangro, Bruno; Varela Calvo, María; (et al.)

Fecha de publicación:

2024

URI:

https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2824%2902526-2
https://hdl.handle.net/10651/78686

ISSN:

0270-9139; 1527-3350